Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 5/20 | 0.37 |
| ▸ | SSTR4 | P31391 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.36 |
| ▸ | SSTR1 | P30872 | 2/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4094266 | 0.74 | RAB9A (0.47) | RAB9AKMT2AMEN1GAASMN1; SMN2 | |
| SCHEMBL25464169 | 0.73 | LMNA (0.50) | RAB9AKMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL9037642 | 0.72 | F2 (0.48) | RAB9AKMT2AGAAHTTSMN1; SMN2 | |
| SCHEMBL25907323 | 0.68 | CHRM3 (0.39) | LMNA | |
| SCHEMBL10169456 | 0.68 | EPHX2 (0.48) | RAB9AKMT2AMEN1HTTSMN1; SMN2 | |
| SCHEMBL4242263 | 0.68 | SMN1; SMN2 (0.35) | RAB9AKMT2AMEN1GAAHTT | |
| SCHEMBL25464213 | 0.67 | NPC1 (0.49) | RAB9AKMT2AMEN1GAAHTT | |
| SCHEMBL3143316 | 0.67 | EPHX1 (0.55) | RAB9AKMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL27749355 | 0.67 | PPARA (0.42) | RAB9AKMT2AMEN1GAAHTT | |
| SCHEMBL25464172 | 0.66 | SSTR4 (0.44) | RAB9AKMT2AALDH1A1NPC1SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101400660-A | Triazole derivative or salt thereof | ASTELLAS PHARMA INC (JP) | 2009-04-01 | — | — | CN | disclosed |
| US-20090082367-A1 | TRIAZOLE DERIVATIVE OR A SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-03-26 | — | — | US | disclosed |
| EP-1995243-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2008-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082367-A1 | TRIAZOLE DERIVATIVE OR A SALT THEREOF | HSD11B1, HSD11B2, HSD17B1 | RAB9A 3659/4885KMT2A 1938/4885MEN1 2335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.